Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab for mixed chimerism in HLH patients after allo-HCT
NCT04944511Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of toripalimab in mixed chimerism, sponsored by Beijing Friendship Hospital. Primary endpoint: Chimeric rate at 4 weeks. Status: unknown.
02
Drugs
toripalimab
03
Conditions
mixed chimerism
Beyond the preview
Go deeper on NCT04944511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944511.